Reply

Please reply to this a positive reply with agreement:                   Newly diagnosed patients with type 2 diabetes that qualify for treatment with an oral antidiabetic do not always need to be placed on metformin as an initial course of treatment (Chisholm-Burns et al., 2022). It is true that metformin is often used as a first-line course of treatment, however, there are many other options as well for patients that cannot tolerate or cannot take metformin (Chisholm-Burns et al., 2022). An example is sulfonylureas. A patient may be prescribed a sulfonylurea as a first line treatment if the patient has any contraindications such as decreased glomerular filtration rate (Chisholm-Burns et al., 2022). Another reason someone may opt for a sulfonylurea is if they are unable to tolerate metformin such as experiencing severe GI upset (Chisholm-Burns et al., 2022).              Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are examples of an antidiabetic medication that can be used for select populations (Chisholm-Burns et al., 2022). GLP-1 RAs not only lower blood glucose levels, but they also regulate gastric emptying and increase satiety (Chisholm-Burns et al., 2022). GLP-1 RAs have also been found to significantly reduce the risk of cardiovascular events and new or worsening nephropathy (Chisholm Burns et al., 2022). This medication can also be prescribed as initial therapy in patients struggling with obesity (Nunns et al., 2025).              Another medication that may be prescribed in addition to antidiabetic medications is an antiplatelet medication such as clopidogrel or aspirin (Chisholm-Burns et al., 2022). This is because cardiovascular disease is one of the most common complications associated with diabetes patients (Moftakhar et al., 2023).              This patient’s condition can be explained by the use of amiodarone. Amiodarone often can cause iatrogenic hypothyroidism (Chisholm-Burns et al., 2022). If this occurs, patient’s must stop amiodarone therapy (Chisholm-Burns et al., 2022). If this line of treatment cannot be discontinued, patients may need to be placed on thyroid replacement therapy (Chisholm-Burns et al., 2022). Factors to consider is weighing the risks vs. benefits of staying on the amiodarone and if there are any alternative options for the treatment of this patient’s recurrent ventricular arrhythmia.